摘要: |
目的:探讨布地奈德联合孟鲁司特钠治疗肺炎支原体肺炎(MPP)患儿的疗效及其对患儿肺功能和炎性细胞因子的影
响。方法:选取2016 年1-4月我院儿科收治的MPP 患儿106例,随机分为观察组和对照组各53例。两组患儿入院后均给予祛
痰、平喘、抗感染等常规治疗,对照组患儿同时给予布地奈德治疗,观察组患儿在对照组治疗基础上联用孟鲁司特钠,疗程均为
10 d。治疗前后采用酶联免疫吸附法(ELISA)检测血清白细胞介素(IL)-6、IL-8、IL-10 及肿瘤坏死因子鄄琢(TNF)水平,采用肺
功能监测仪检测潮气量(VT)、达峰时间比(TPTEF/TE)、呼出25%潮气量时的瞬间流速与呼气峰流速比(TEF25/PTEF),比较
两组总有效率及不良反应发生率。结果:治疗后,两组患儿IL-6、IL-8、TNF-γ水平均降低,IL-10 水平均升高,VT、TPTEF/TE、
TEF25/PTEF 均明显改善,且治疗时间越长改善越明显(P均<0.05),观察组患儿改善程度均优于对照组(P均<0.05)。观察组
总有效率92.45% ,高于对照组的81.13% (P<0.05),两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:布地奈
德联合孟鲁司特钠可有效改善MPP患儿的肺功能,降低血清炎性细胞因子水平,提高临床疗效,且不会增加不良反应,安全
性较好。 |
关键词: 肺炎支原体肺炎 布地奈德 孟鲁司特钠 肺功能 炎性细胞因子 |
DOI:doi: 10.13407/j.cnki.jpp.1672-108X.2017.12.021 |
|
基金项目: |
|
Clinical Effect of Budesonide Combined with Montelukast in Treatment of Children with MycoplasmaPneumoniae Pneumonia and Its Effects on Pulmonary Function and Inflammatory Cytokines |
|
() |
Abstract: |
Objective: To investigate the clinical effect of budesonide combined with montelukast in the treatment of children with
Mycoplasma pneumoniae pneumonia (MPP) and its effects on pulmonary function and inflammatory cytokines. Methods: A total of
106 children with MPP in our hospital from January to April 2016 were collected and randomly assigned into observation group and
control group with 53 children in each group. All children received expectorant, anti-asthmatic and anti-infection therapy. Children in
the control group received budesonide treatment on the basis of primary treatment. Children in the observation group received
montelukast sodium on the basis of control group. Before and after treatment, the levels of IL-6, IL-8, IL-10, TNF-r were detected
by ELISA assay. VT, TPTEF/ TE, TEF25/ PTEF were detected by pulmonary function monitor. The total effective rate and adverse
reaction rate were compared between the two groups. Results: After treatment, the levels of IL-6, IL-8, TNF-r of two groups were
significantly decreased, the levels of IL-10 were significantly increased, the VT, TPTEF/TE, TEF25/PTEF were significantly
improved, along with the treatment time extension increased more significantly (P<0.05), and the observation group improved more
than the control group (P<0.05). The total effective rate of the observation group was significantly higher than that of the control
group (92.45% vs 81.13% , P<0.05), while there was no significant difference in the incidence of adverse reactions between the
two groups (P>0.05). Conclusion: Budesonide combined with montelukast sodium can effectively improve pulmonary function,
reduce serum inflammatory cytokines levels, improve clinical total effective rate and not increase adverse reaction rate. |
Key words: Mycoplasma pneumoniae pneumonia budesonide montelukast sodium pulmonary function inflammatory cytokines |